Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioNTech AG

www.biontech.de

Latest From BioNTech AG

Venture Funding Deals: July Sees Seven Rounds Of $100m Or More

Century Therapeutics brings in $250m for its cell therapy programs in a series A round, while immunotherapy specialist BioNTech sets a record for series B, raising $350m. Another five firms brought in rounds of $100m or greater...

Deals Financing

Finance Watch: High Value Of Exits Keep Biopharma VC Deals At Near-Record Levels

Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.

Financing Deals

Finance Watch: Among Multiple Mega-Rounds, Revolution Raises $100m For RAS Programs

Private Company Edition: Revolution Medicines follows its Sanofi partnership and Warp Drive Bio buyout with a series C venture capital round to fund its RAS pathway inhibitors in cancer. The financing came during a boom in $100m-plus VC financings, including BioNTech's $325m series B.

Financing Business Strategies

BioNTech Fills Coffers With Extra $325m Via Series B Financing

Mainz-based BioNTech raises $325m in an upsized series B round to further advance its individualized immuno-oncology pipeline and manufacturing infrastructure.

Commercial Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • BioNTech AG
  • Senior Management
  • Ugur Sahin, MD, CEO
    Sierk Poetting, PhD, CFO & COO
    Sean Marett, CBO & Chief Commercial Officer
    Özlem Türeci , MD, CMO
  • Contact Info
  • BioNTech AG
    Phone: 6131 9084 0
    An der Goldgrube 12
    Mainz, D-55131
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register